摘要
目的观察DC-CIK联合替吉奥治疗老年晚期胃癌的近期疗效和不良反应。方法将49例老年晚期胃癌患者随机分为两组。联合组(n=25):采用替吉奥胶囊联合DC-CIK治疗。单药组(n=24):采用单药替吉奥治疗。根据EORTC QLQ-C30生活质量问卷分析两组患者生活质量上的差异,并观察两组疗效。结果两组疗效相似,无统计学差异(P>0.05),联合组患者的躯体功能和总生活质量得到了改善,包括食欲、睡眠、疲乏、恶心、呕吐,且CEA、CA242较单药组下降更为明显(P<0.05)。结论 DC-CIK联合替吉奥治疗老年晚期胃癌疗效确切,且能改善患者的生活质量,使症状和体征改善,显著降低血清中系列肿瘤标记物的水平。
Objective To investigate the recent efficacy of S-1 combined dendritic cell（ DC） plus cytokine killer（ CIK）（ DC / CIK）in the treatment of elderly patients with advanced gastric cancer. Methods Forty-nine elderly patients with advanced gastric cancer were randomized into two groups,i. e. trial group（ n = 25） treated with S-1 combined with DC / CIK cell transfusion and control group（ n = 24） treated with S-1 alone. Results The two groups reached similar recent efficacy（ P〈0. 05）. But the trial group had improvements in physical functions and overall quality of life. Also,the values of tumor biomarkers,such as carcinoembryonic antigen（ CEA） and CA242,were decreased more dramatically in the trial group than the control group（ P〈0. 05）. Conclusion DC-CIK combined with S-1 has efficacy on elderly patients with advanced gastric cancer,and can improve the patient＇s quality of life. It also can significantly decrease serum tumor markers.
出处
《临床军医杂志》
CAS
2015年第2期132-135,共4页
Clinical Journal of Medical Officers
